EXECUTIVE EDITORS
Bruce E. Johnson, MD, FASCO, ASCO Immediate Past President, Dana-Farber Cancer Institute, Boston, MA
Sumanta K. Pal, MD, City of Hope Comprehensive Cancer Center, Duarte, CA
Richard L. Schilsky, MD, FACP, FSCT, FASCO, ASCO Senior Vice President and Chief Medical Officer, Alexandria, VA

RESEARCH PRIORITY EDITORS
Mariana Chavez-MacGregor, MD, University of Texas MD Anderson Cancer Center, Houston, TX
Heidi D. Klepin, MD, MS, Wake Forest Baptist Medical Center, Winston Salem, NC
Elizabeth A. Mittendorf, MD, PhD, Dana-Farber Cancer Institute, Boston, MA

SPECIALTY EDITORS
Neeraj Agarwal, MD, Huntsman Cancer Institute, Salt Lake City, UT
Susan Marina Chang, MD, University of California, San Francisco, CA
Ezra Cohen, MD, FRCPC, University of California, San Diego, CA
Suzanne Cole, MD, FACP, Mercy Clinic Oncology and Hematology, Oklahoma City, OK
William Dale, MD, PhD, City of Hope National Medical Center, Duarte, CA
Catherine S. Magid Diefenbach, MD, New York University Cancer Center, New York, NY
Mary L. Disis, MD, FASCO, University of Washington, Seattle, WA
Robert Dreicer, MD, MS, MACP, FASCO, University of Virginia Cancer Center, Charlottesville, VA
David L. Graham, MD, FASCO, Levine Cancer Institute, Charlotte, NC
N. Lynn Henry, MD, PhD, FACP, Huntsman Cancer Institute, Salt Lake City, UT
Joshua Jones, MD, MA, University of Pennsylvania Health System, Philadelphia, PA
Vicki Keedy, MD, Vanderbilt University Medical Center, Nashville, TN
Merry Jennifer Markham, MD, FACP, University of Florida, Gainesville, FL
Carlos Rodriguez-Galindo, MD, St. Jude Children's Research Hospital, Memphis, TN
Michael S. Sabel, MD, FACS, University of Michigan, Ann Arbor, MI
Mario Sznol, MD, Yale School of Medicine, New Haven, CT
William D. Tap, MD, Memorial Sloan Kettering Cancer Center, New York, NY
Shannon Neville Westin, MD, University of Texas MD Anderson Cancer Center, Houston, TX

ACKNOWLEDGEMENT
The editors would like to thank Michael J. Miller, MS, MPH, for his work drafting this report.
The editors would also like to thank Edward S. Kim, MD, and Jennifer Ligibel, MD, for their input, and posthumously thank Arti Hurria, MD, FASCO, an oncologist whose life-long commitment to improving the care of geriatric patients with cancer has forever made a difference.

Disclosures for editorial board members can be viewed on page 46.
The following represents disclosure information provided by Clinical Cancer Advances 2019 editorial board members. All relationships are considered compensated. Relationships are self-held unless noted. I = Immediate Family Member, Inst = My Institution. Relationships may not relate to the subject matter of this report. For more information about ASCO’s conflict of interest policy, please refer to asco.org/rwc or ascopubs.org/jco/site/ifc.

Sumanta K. Pal
Honoraria: Novartis, Medivation, Astellas Pharma
Consulting or Advisory Role: Pfizer, Novartis, Aveo, Myriad Pharmaceuticals, Genentech, Exelixis, Bristol-Myers Squibb, Astellas Pharma, Ipsen, Eisai
Research Funding: Medivation

Neeraj Agarwal
Consulting or Advisory Role: Pfizer, Exelixis, Medivation/Astellas, Eisai, Merck, Novartis, EMD Serono, Clovis Oncology, Genentech, Bristol-Myers Squibb, AstraZeneca, Nektar, Eli Lilly, Bayer, Foundation One, Argos Therapeutics
Research Funding: Bayer (Inst), Bristol-Myers Squibb (Inst), GlaxoSmithKline (Inst), Medivation (Inst), Takeda (Inst), Novartis (Inst), Pfizer (Inst), BN ImmunoTherapeutics (Inst), Exelixis (Inst), TRACON Pharma (Inst), Rexahn Pharmaceuticals (Inst), Amgen (Inst), AstraZeneca (Inst), Active Biotech (Inst), Bavarian Nordic (Inst), Calithera Biosciences (Inst), Celldex (Inst), Eisai (Inst), Genentech (Inst), Immunomedics (Inst), Janssen (Inst), Merck (Inst), Newlink Genetics (Inst), Prometheus (Inst), Sanofi (Inst)

Susan Marina Chang
Consulting or Advisory Role: Tocagen
Research Funding: Novartis (Inst), Agios (Inst)

Marina Chavez-MacGregor
Employment: MD Anderson Physician’s Network
Honoraria: Pfizer
Consulting or Advisory Role: Genentech
Research Funding: Novartis (Inst)
Travel, Accommodations, Expenses: Pfizer

Ezra Cohen
Consulting or Advisory Role: Merck, Bristol-Myers Squibb, AstraZeneca, Human Longevity, Pfizer, EMD Serono, Mavu Pharmaceutical, Nanobiotix, Incyte

Suzanne Cole
Honoraria: Research to Practice

Catherine S. Magid Diefenbach
Stock and Other Ownership Interests: Gilead Sciences
Consulting or Advisory Role: Seattle Genetics, Bayer, Bristol-Myers Squibb, Genentech, Merck
Research Funding: Seattle Genetics (Inst), Genentech (Inst), Incyte (Inst), LAM Therapeutics (Inst), Merck (Inst), Bristol-Myers Squibb (Inst), Millennium (Inst), MEI Pharma (Inst)

Mary L. Disis
Stock and Other Ownership Interests: Epithan
Research Funding: EMD Serono, Celgene, Janssen, Epithan (Inst), Pfizer
Patents, Royalties, Other Intellectual Property: I am an inventor on patents held by the University of Washington

Robert Dreicer
Consulting or Advisory Role: Astellas Pharma, AstraZeneca, Bristol-Myers Squibb, Genentech, EMD Serono, Incyte, Pfizer
Research Funding: Genentech (Inst), Seattle Genetics (Inst), BioClin Therapeutics (Inst), Janssen Oncology (Inst), Merck (Inst)

David L. Graham
Employment: Medscape
Speakers’ Bureau: Biopep Solution

N. Lynn Henry
Research Funding: Innocrin Pharma (Inst), Pfizer (Inst), AbbVie (Inst)

Vicki Keeley
Employment: Zimmer Biomet (I)
Consulting or Advisory Role: Threshold Pharmaceuticals, Janssen Oncology, Karyopharm Therapeutics

Heidi D. Klepin
Patents, Royalties, Other Intellectual Property: UpToDate contributor

Merry Jennifer Markham
Consulting or Advisory Role: Astex Pharmaceuticals
Research Funding: Astex Pharmaceuticals (Inst), Aduro Biotech (Inst)

Elizabeth A. Mittendorf
Honoraria: Physician Education Resource
Consulting or Advisory Role: Peregrine Pharmaceuticals, TapImmune, Sellas Life Sciences, Merck
Research Funding: Galena Biopharma (Inst), Genentech, AstraZeneca (Inst), EMD Serono (Inst)

Carlos Rodriguez-Galindo
Honoraria: Novimmune

Michael S. Sabel
Patents, Royalties, Other Intellectual Property: Breast Cancer Ally and Melanoma Ally mobile technologies

Richard L. Schilsky
Research Funding: AstraZeneca (Inst), Bayer (Inst), Bristol-Myers Squibb (Inst), Genentech (Inst), Eli Lilly (Inst), Merck (Inst), Pfizer (Inst)

Mario Szol
Stock and Other Ownership Interests: Amphivena, Intensity Therapeutics, Adaptive Biotechnologies, Actym Therapeutics, Torque
Consulting or Advisory Role: Bristol-Myers Squibb, Genentech, AstraZeneca/MedImmune, Kyowa Hakko Kirin, Nektar, Novartis, Eli Lilly, Merck Sharp & Dohme, Biodex, Adapimmune, Lycera, Theravance, Modulate, Omniox, Seattle Genetics, Inovio Pharmaceuticals, Pierre Fabre, Baxalta/Shire, Newlink Genetics, Molecular Partners, Genmab, Torque, Abbie, Allakos, Hinge, Symphogen, Pieris Pharmaceuticals, Gritstone Oncology, Innate Pharma, Celldex, Incyte, Almac Diagnostics, Immunoconore

Other Relationship: Haymarket Media, Research to Practice, TRM Oncology, Physician Education Resource, Imedex, AcademicCME, DAVAOncology, Clinical Care Options, Vendico, Prime Oncology

William D. Tap
Leadership: Certis Oncology Solutions, Atropos Pharmaceuticals
Stock and Other Ownership Interests: Certis Oncology Solutions, Atropos
Consulting or Advisory Role: EMD Serono, Plexxikon, Janssen, Eli Lilly, Daiichi Sankyo, Novartis, Eisai, Immune Design, Blueprint Medicines, Loxo, Agios, GlaxoSmithKline
Research Funding: Novartis, Eli Lilly, Plexxikon, Daiichi Sankyo, TRACON Pharma, Blueprint Medicine, Immune Design
Patents, Royalties, Other Intellectual Property: Methods of treating metastatic sarcoma using talimogene laherparepvec (T-Vec) and pembrolizumab combination therapy, 62/671,625; companion diagnostic for metastatic sarcoma using talimogene laherparepvec (T-Vec) and pembrolizumab combination therapy, 62/671,625; companion diagnostic for CDK4 inhibitors, 14/854,329

Shannon Neville Westin
Consulting or Advisory Role: Roche, AstraZeneca, Ovation Sciences, Medivation, Genentech, Vermillion, Casdin Capital, Medscape, Clovis Oncology, Watermark Research Partners, Gerson Lehrman Group, Vaniam Group, Tesaro, Merck, Pfizer, BioAscent
Research Funding: AstraZeneca, Novartis, Biomarin, Karyopharm Therapeutics (I), Celgene (I), Critical Outcome Technologies, Bayer, Tesaro, Kite Pharma (I), Cottinga Pharmaceuticals, Clovis Oncology, Genentech

Bruce E. Johnson
Research Funding: Novartis (Inst), Toshiba (Inst), Novartis (Inst)
Patents, Royalties, Other Intellectual Property: Dana-Farber Cancer Institute

No other potential conflicts of interest were reported.